ATE313559T1 - Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen - Google Patents

Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen

Info

Publication number
ATE313559T1
ATE313559T1 AT00966633T AT00966633T ATE313559T1 AT E313559 T1 ATE313559 T1 AT E313559T1 AT 00966633 T AT00966633 T AT 00966633T AT 00966633 T AT00966633 T AT 00966633T AT E313559 T1 ATE313559 T1 AT E313559T1
Authority
AT
Austria
Prior art keywords
peptide
carrier
hpv
vlp
introducing
Prior art date
Application number
AT00966633T
Other languages
English (en)
Inventor
Per Antonsson
Karin Kristensson
Marie Wallen-Oehman
Joakim Dillner
Peter Lando
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Application granted granted Critical
Publication of ATE313559T1 publication Critical patent/ATE313559T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Otolaryngology (AREA)
AT00966633T 1999-09-30 2000-09-19 Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen ATE313559T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903534A SE514982C2 (sv) 1999-09-30 1999-09-30 Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
PCT/SE2000/001808 WO2001023422A1 (en) 1999-09-30 2000-09-19 Vaccine

Publications (1)

Publication Number Publication Date
ATE313559T1 true ATE313559T1 (de) 2006-01-15

Family

ID=20417209

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00966633T ATE313559T1 (de) 1999-09-30 2000-09-19 Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen

Country Status (25)

Country Link
EP (1) EP1222200B1 (de)
JP (1) JP2003510064A (de)
KR (1) KR20020047195A (de)
CN (1) CN1373771A (de)
AT (1) ATE313559T1 (de)
AU (1) AU771481B2 (de)
BR (1) BR0014666A (de)
CA (1) CA2384723A1 (de)
CZ (1) CZ20021023A3 (de)
DE (1) DE60025016D1 (de)
EE (1) EE200200157A (de)
HR (1) HRP20020092A2 (de)
HU (1) HUP0202770A3 (de)
IL (1) IL148741A0 (de)
MX (1) MXPA02003328A (de)
NO (1) NO20020615L (de)
NZ (1) NZ516725A (de)
PL (1) PL355012A1 (de)
RU (1) RU2002111554A (de)
SE (1) SE514982C2 (de)
SK (1) SK4222002A3 (de)
TR (1) TR200200802T2 (de)
WO (1) WO2001023422A1 (de)
YU (1) YU22202A (de)
ZA (1) ZA200200886B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
ATE466022T1 (de) * 2004-03-24 2010-05-15 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
DE102004036913A1 (de) * 2004-07-16 2006-02-09 Responsif Gmbh Verwendung von Pentameren zur Herstellung eines Medikaments
CN1796403B (zh) * 2004-12-22 2010-04-28 三峡大学 用于多型人乳头瘤病毒感染防治的多肽和疫苗
CN100392084C (zh) * 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
CN101914139B (zh) * 2010-07-16 2012-11-21 四川大学 人类乳头瘤病毒(hpv)衣壳蛋白l1多肽及其制备与应用
CN110891602A (zh) 2017-06-23 2020-03-17 帕多瓦有限责任公司 嵌合病毒样颗粒以及其作为免疫反应的抗原特异性重定向剂的用途
JP7641005B2 (ja) 2018-12-27 2025-03-06 ヴェリミューン インコーポレイテッド コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
CN113454210A (zh) * 2019-02-08 2021-09-28 伦斯勒理工大学 基于精子相关蛋白catsper的避孕疫苗
MX2023004465A (es) 2020-10-19 2023-06-19 Verimmune Inc Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1728800A1 (de) * 1994-10-07 2006-12-06 Loyola University Of Chicago Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique
DE19812941A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor

Also Published As

Publication number Publication date
SK4222002A3 (en) 2002-10-08
HRP20020092A2 (en) 2003-06-30
YU22202A (sh) 2005-06-10
WO2001023422A1 (en) 2001-04-05
JP2003510064A (ja) 2003-03-18
ZA200200886B (en) 2003-03-26
EP1222200A1 (de) 2002-07-17
HUP0202770A2 (hu) 2002-12-28
AU771481B2 (en) 2004-03-25
DE60025016D1 (de) 2006-01-26
BR0014666A (pt) 2002-06-18
TR200200802T2 (tr) 2002-09-23
NO20020615D0 (no) 2002-02-08
NZ516725A (en) 2003-03-28
IL148741A0 (en) 2002-09-12
CA2384723A1 (en) 2001-04-05
RU2002111554A (ru) 2004-03-27
SE514982C2 (sv) 2001-05-28
EE200200157A (et) 2003-04-15
NO20020615L (no) 2002-05-29
CZ20021023A3 (cs) 2002-07-17
HUP0202770A3 (en) 2004-07-28
AU7695100A (en) 2001-04-30
MXPA02003328A (es) 2004-09-10
SE9903534L (sv) 2001-03-31
PL355012A1 (en) 2004-03-22
EP1222200B1 (de) 2005-12-21
SE9903534D0 (sv) 1999-09-30
KR20020047195A (ko) 2002-06-21
CN1373771A (zh) 2002-10-09

Similar Documents

Publication Publication Date Title
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
JP2012010713A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
DE69731289D1 (de) Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
DE60025016D1 (de) Fusionsprotein aus HPV-L1 und einem Peptid, das ein VLP bilden kann und als Vehikel zum EInschleusen eines Peptids in eine Zelle dienen kann, sowie dessen medizinische Verwendungen
RU2006131598A (ru) Рекомбинантный белок, несущий эпитопы вируса папилломы человека, встроенные в белок аденилатциклазу или его фрагмент, его терапевтическое применение
UY24367A1 (es) Vacunas contra tumores y procedimiento para su produccion
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
CA2283462A1 (en) Vectors having enhanced expression and methods of making and uses thereof
BR9913026A (pt) Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
KR930702522A (ko) 인체의 투명층 단백질 제트피 3 (zp3)
Horváth et al. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage
CN106955361A (zh) 一种含有结核病变态反应原ce的药物组合物
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
SI1506222T1 (sl) Himerni L1-proteini humanega papilomavirusa 16, ki obsegajo L2-peptid, delci, podobni virusu, pripravljeni iz njih, in postopek za pripravo delcev
NO20032097D0 (no) Gj¶ravledet vaksine mot IPNV
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação
AU6233501A (en) Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide
CN102559725A (zh) 人干细胞生长因子及其聚乙二醇修饰化产物的生产方法及用途
PL363501A1 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
ATE463566T1 (de) Tumor- und seneszenzsmarker
DE60018605D1 (de) Ing2, ein mit iaps assoziiertes zellzyklusprotein, sowie zusammensetzungen, verfahren und verwendungen
AU2002223860A1 (en) Nucleic acid vaccine comprising a fusion protein including an adjuvant sequence from a plant viral coat protein
FR2603040A1 (fr) Proteine, sequence d'adn, poxvirus, cellules et leur procede de culture, ainsi que les compositions pharmaceutiques les contenant, utiles dans la prevention de la schistosomose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties